{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:09:44Z","timestamp":1792073384188,"version":"4.4.0"},"reference-count":44,"publisher":"The Microbiological Society of Korea","issue":"7","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Microbiol."],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12275-023-00062-4","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:03:18Z","timestamp":1687780998000},"page":"703-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches"],"prefix":"10.71150","volume":"61","author":[{"given":"Hee-Jung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanul","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Nowakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Woo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1681-5557","authenticated-orcid":false,"given":"Young Bong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4586","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"62_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","volume":"21","author":"B Batchuluun","year":"2022","unstructured":"Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022). Lipogenesis inhibitors: Therapeutic opportunities and challenges. Nature Reviews Drug Discovery, 21, 283\u2013305.","journal-title":"Nature Reviews Drug Discovery"},{"key":"62_CR2","doi-asserted-by":"publisher","first-page":"110127","DOI":"10.1016\/j.mehy.2020.110127","volume":"143","author":"K Buschard","year":"2020","unstructured":"Buschard, K. (2020). Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. Medical Hypotheses, 143, 110127.","journal-title":"Medical Hypotheses"},{"key":"62_CR3","doi-asserted-by":"publisher","first-page":"704205","DOI":"10.3389\/fphar.2021.704205","volume":"12","author":"C Chakraborty","year":"2021","unstructured":"Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S. S. (2021). The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: Lessons learned from major clinical studies. Frontiers in Pharmacology, 12, 704205.","journal-title":"Frontiers in Pharmacology"},{"key":"62_CR4","doi-asserted-by":"publisher","first-page":"105788","DOI":"10.1016\/j.compbiomed.2022.105788","volume":"147","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty, R., Bhattacharje, G., Baral, J., Manna, B., Mullick, J., Mathapati, B. S., Abraham, P. J. M., Hasija, Y., & Ghosh, A. (2022). In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2. Computers in Biology and\nMedicine, 147, 105788.","journal-title":"Computers in Biology and Medicine"},{"key":"62_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1128\/CMR.00102-14","volume":"28","author":"JF Chan","year":"2015","unstructured":"Chan, J. F., Lau, S. K., To, K. K., Cheng, V. C., Woo, P. C., & Yuen, K. Y. (2015). Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews, 28, 465\u2013522.","journal-title":"Clinical Microbiology Reviews"},{"key":"62_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"JF Chan","year":"2020","unstructured":"Chan, J. F., Kok, K. H., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. Y. (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections, 9, 221\u2013236.","journal-title":"Emerging Microbes & Infections"},{"key":"62_CR7","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1038\/s41598-022-08320-y","volume":"12","author":"WKB Chan","year":"2022","unstructured":"Chan, W. K. B., Olson, K. M., Wotring, J. W., Sexton, J. Z., Carlson, H. A., & Traynor, J. R. (2022). In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs. Scientific\nReports, 12, 5320.","journal-title":"Scientific Reports"},{"key":"62_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1128\/CMR.00023-07","volume":"20","author":"VCC Cheng","year":"2007","unstructured":"Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007). Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clinical Microbiology Reviews, 20, 660\u2013694.","journal-title":"Clinical Microbiology Reviews"},{"key":"62_CR9","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/s42255-022-00698-3","volume":"4","author":"JA Chirinos","year":"2022","unstructured":"Chirinos, J. A., Lopez-Jaramillo, P., Giamarellos-Bourboulis, E. J., D\u00e1vila-del-Carpio, G. H., Bizri, A. R., Andrade-Villanueva, J. F., Salman, O., Cure-Cure, C., Rosado-Santander, N. R., Giraldo, C., M. P., et al. (2022). A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019. Nature Metabolism, 4, 1847\u20131857.","journal-title":"Nature Metabolism"},{"key":"62_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3389\/fimmu.2020.01664","volume":"11","author":"S Choudhary","year":"2020","unstructured":"Choudhary, S., Malik, Y. S., & Tomar, S. (2020). Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach. Frontiers in Immunology, 11, 1664.","journal-title":"Frontiers in Immunology"},{"key":"62_CR11","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1038\/s41598-021-92966-7","volume":"11","author":"KR Crakes","year":"2021","unstructured":"Crakes, K. R., Pires, J., Quach, N., Ellis-Reis, R. E., Greathouse, R., Chittum, K. A., Steiner, J. M., Pesavento, P., Marks, S. L., Dandekar, S., et al. (2021). Fenofibrate promotes PPAR\u03b1-targeted recovery of the intestinal epithelial barrier at the host-microbe interface in dogs with diabetes mellitus. Scientific Reports, 11, 13454.","journal-title":"Scientific Reports"},{"key":"62_CR12","doi-asserted-by":"publisher","first-page":"791267","DOI":"10.3389\/fimmu.2022.791267","volume":"13","author":"J Dai","year":"2022","unstructured":"Dai, J., Wang, H., Liao, Y., Tan, L., Sun, Y., Song, C., Liu, W., Qiu, X., & Ding, C. (2022). Coronavirus infection and cholesterol metabolism. Frontiers in Immunology, 13, 791267.","journal-title":"Frontiers in Immunology"},{"key":"62_CR13","doi-asserted-by":"publisher","first-page":"660490","DOI":"10.3389\/fphar.2021.660490","volume":"12","author":"SP Davies","year":"2021","unstructured":"Davies, S. P., Mycroft-West, C. J., Pagani, I., Hill, H. J., Chen, Y. H., Karlsson, R., Bagdonaite, I., Guimond, S. E., Stamataki, Z., De Lima, M. A., et al. (2021). The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models. Frontiers in Pharmacology, 12, 660490.","journal-title":"Frontiers in Pharmacology"},{"key":"62_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020). Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Central Science, 6, 672\u2013683.","journal-title":"ACS Central Science"},{"key":"62_CR15","doi-asserted-by":"publisher","first-page":"e79946","DOI":"10.7554\/eLife.79946","volume":"12","author":"A Ehrlich","year":"2023","unstructured":"Ehrlich, A., Ioannidis, K., Nasar, M., Abu Alkian, I., Daskal, Y., Atari, N., Kliker, L., Rainy, N., Hofree, M., Tikva, S., et al. (2023). Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: In vitro, observational, and non-randomized open-label interventional study. eLife, 12, e79946.","journal-title":"eLife"},{"key":"62_CR16","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1161\/01.CIR.100.4.e20","volume":"100","author":"SE Epstein","year":"1999","unstructured":"Epstein, S. E., Zhou, Y. F., & Zhu, J. (1999). Infection and atherosclerosis: Emerging mechanistic paradigms. Circulation, 100, e20\u2013e28.","journal-title":"Circulation"},{"key":"62_CR17","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3390\/vaccines10101731","volume":"10","author":"I Gentile","year":"2022","unstructured":"Gentile, I., Scotto, R., Schiano Moriello, N., Pinchera, B., Villari, R., Trucillo, E., Federico Ii Covid Team. (2022). Nirmatrelvir\/ritonavir and molnupiravir in the treatment of mild\/moderate COVID-19: results of a real-life study. Vaccines, 10, 1731.","journal-title":"Vaccines"},{"key":"62_CR18","doi-asserted-by":"publisher","first-page":"750544","DOI":"10.3389\/fphys.2021.750544","volume":"12","author":"M Glitscher","year":"2021","unstructured":"Glitscher, M., & Hildt, E. (2021). Endosomal cholesterol in viral infections\u2014a common denominator? Frontiers in Physiology, 12, 750544.","journal-title":"Frontiers in Physiology"},{"key":"62_CR19","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & G\u00f6tte, M. (2020). Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. The Journal of Biological Chemistry, 295, 6785\u20136797.","journal-title":"The Journal of Biological Chemistry"},{"key":"62_CR20","doi-asserted-by":"publisher","first-page":"eabh3032","DOI":"10.1126\/sciadv.abh3032","volume":"7","author":"N Han","year":"2021","unstructured":"Han, N., Hwang, W., Tzelepis, K., Schmerer, P., Yankova, E., MacMahon, M., Lei, W. M., Katritsis, N., Liu, A., Felgenhauer, U., et al. (2021). Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies. Science Advances, 7, eabh3032.","journal-title":"Science Advances"},{"key":"62_CR21","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1002\/hsr2.671","volume":"5","author":"T Islam","year":"2022","unstructured":"Islam, T., Hasan, M., Rahman, M. S., & Islam, M. R. (2022). Comparative evaluation of authorized drugs for treating Covid-19 patients. Health Science Reports, 5, e671.","journal-title":"Health Science Reports"},{"key":"62_CR22","doi-asserted-by":"crossref","unstructured":"Jang, W. D., Jeon, S., Kim, S., & Lee, S. Y. (2021). Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proceedings of the National Academy of Sciences of the USA, 118, e2024302118.","DOI":"10.1073\/pnas.2024302118"},{"key":"62_CR23","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1021\/acs.jproteome.0c00383","volume":"19","author":"I Maffucci","year":"2020","unstructured":"Maffucci, I., & Contini, A. (2020). In silico drug repurposing for SARS-CoV-2 main proteinase and spike proteins. Journal of Proteome Research, 19, 4637\u20134648.","journal-title":"Journal of Proteome Research"},{"key":"62_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bj.2020.11.005","volume":"44","author":"P Magro","year":"2021","unstructured":"Magro, P., Zanella, I., Pescarolo, M., Castelli, F., & Quiros-Roldan, E. (2021). Lopinavir\/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. Biomed Journal, 44, 43\u201353.","journal-title":"Biomed Journal"},{"key":"62_CR25","doi-asserted-by":"crossref","unstructured":"Malin, J. J., Su\u00e1rez, I., Priesner, V., Fatkenheuer, G., & Rybniker, J. (2020). Remdesivir against COVID-19 and other viral Diseases. Clinical Microbiology Reviews, 34, e00162\u201320.","DOI":"10.1128\/CMR.00162-20"},{"key":"62_CR26","doi-asserted-by":"publisher","first-page":"105318","DOI":"10.1016\/j.meegid.2022.105318","volume":"103","author":"S Mirmohammadi","year":"2022","unstructured":"Mirmohammadi, S., Kianmehr, A., Sabbaghian, A., Mohebbi, A., Shahbazmohammadi, H., Sheykharabi, M., & Bazzi, Z. (2022). In silico drug repurposing against SARS-CoV-2 using an integrative transcriptomic profiling approach: Hydrocortisone and Benzhydrocodone as potential drug candidates against COVID-19. Infection, Genetics and Evolution, 103, 105318.","journal-title":"Infection, Genetics and Evolution"},{"key":"62_CR27","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.7573\/dic.2020-4-14","volume":"9","author":"J Pardo","year":"2020","unstructured":"Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A. (2020). The journey of remdesivir: From Ebola to COVID-19. Drugs in Context, 9, 2020\u20132024.","journal-title":"Drugs in Context"},{"key":"62_CR28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s10787-017-0428-y","volume":"26","author":"GS Prasad","year":"2018","unstructured":"Prasad, G. S., Govardhan, P., Deepika, G., Vakdevi, V., & Sashidhar, R. B. (2018). Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies. Inflammopharmacology, 26, 973\u2013981.","journal-title":"Inflammopharmacology"},{"key":"62_CR29","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.3390\/molecules27092723","volume":"27","author":"L Rodrigues","year":"2022","unstructured":"Rodrigues, L., Bento Cunha, R., Vassilevskaia, T., Viveiros, M., & Cunha, C. (2022). Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates. Molecules, 27, 2723.","journal-title":"Molecules"},{"key":"62_CR30","doi-asserted-by":"publisher","first-page":"e2029058","DOI":"10.1001\/jamanetworkopen.2020.29058","volume":"3","author":"N Rosenthal","year":"2020","unstructured":"Rosenthal, N., Cao, Z., Gundrum, J., Sianis, J., & Safo, S. (2020). Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Network Open, 3, e2029058.","journal-title":"JAMA Network Open"},{"key":"62_CR31","doi-asserted-by":"publisher","first-page":"e35427","DOI":"10.1371\/journal.pone.0035427","volume":"7","author":"N Sehgal","year":"2012","unstructured":"Sehgal, N., Kumawat, K. L., Basu, A., & Ravindranath, V. (2012). Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of japanese encephalitis viral infection. PLoS ONE, 7, e35427.","journal-title":"PLoS ONE"},{"key":"62_CR32","unstructured":"Sidhu, G., & Tripp, J. (2022). Fenofibrate. Treasure Island (FL). StatPearls Publishing."},{"key":"62_CR33","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/cts.12310","volume":"8","author":"AJ Stolarz","year":"2015","unstructured":"Stolarz, A. J., Farris, R. A., Wiley, C. A., O\u2019Brien, C. E., & Price, E. T. (2015). Fenofibrate attenuates neutrophilic inflammation in airway epithelia: Potential drug repurposing for cystic fibrosis. Clinical Translational Science, 8, 696\u2013701.","journal-title":"Clinical Translational Science"},{"key":"62_CR34","doi-asserted-by":"publisher","first-page":"e0233722","DOI":"10.1128\/spectrum.02337-22","volume":"11","author":"L Tao","year":"2023","unstructured":"Tao, L., Dryden, P., Lowe, A., Wang, G., Achuthkumar, A., Chang, T., & Reese, T. A. (2023). WY14643 increases herpesvirus replication and inhibits IFN\u03b2 production independently of PPAR\u03b1 expression. Microbiology Spectrum, 11, e0233722.","journal-title":"Microbiology Spectrum"},{"key":"62_CR35","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.jlr.2021.100129","volume":"62","author":"KN Theken","year":"2021","unstructured":"Theken, K. N., Tang, S. Y., Sengupta, S., & FitzGerald, G. A. (2021). The roles of lipids in SARS-CoV-2 viral replication and the host immune response. Journal of Lipid Research, 62, 100129. https:\/\/doi.org\/10.1016\/j.jlr.2021.100129.","journal-title":"Journal of Lipid Research"},{"key":"62_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30, 269\u2013271.","journal-title":"Cell Research"},{"key":"62_CR37","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1002\/mco2.157","volume":"3","author":"T Wang","year":"2022","unstructured":"Wang, T., Cao, Y., Zhang, H., Wang, Z., Man, C. H., Yang, Y., Chen, L., Xu, S., Yan, X., Zheng, Q., et al. (2022). COVID-19 metabolism: Mechanisms and therapeutic targets. MedComm, 3, e157.","journal-title":"MedComm"},{"key":"62_CR38","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","volume":"54","author":"W Wen","year":"2022","unstructured":"Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., Zhou, X., Wu, Q., Zhang, X., Feng, Z., et al. (2022). Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: A meta-analysis. Annals of Medicine, 54, 516\u2013523.","journal-title":"Annals of Medicine"},{"key":"62_CR39","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. Journal Of The American Medical Association, 324, 782\u2013793.","journal-title":"Journal Of The American Medical Association"},{"key":"62_CR40","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"CKH Wong","year":"2022","unstructured":"Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022). Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An observational study. Lancet, 400, 1213\u20131222.","journal-title":"Lancet"},{"key":"62_CR41","doi-asserted-by":"publisher","first-page":"786348","DOI":"10.3389\/fcimb.2021.786348","volume":"11","author":"W Wu","year":"2021","unstructured":"Wu, W., Luo, X., & Ren, M. (2021). Clearance or hijack: Universal interplay mechanisms between viruses and host autophagy from plants to animals. Frontiers in Cellular and Infection Microbiology, 11, 786348.","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"62_CR42","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/02713683.2019.1622020","volume":"44","author":"PT Yeh","year":"2019","unstructured":"Yeh, P. T., Wang, L. C., Chang, S. W., Yang, W. S., Yang, C. M., & Yang, C. H. (2019). Effect of fenofibrate on the expression of inflammatory mediators in a diabetic rat model. Current Eye Research, 44, 1121\u20131132.","journal-title":"Current Eye Research"},{"key":"62_CR43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/v14061203","volume":"14","author":"L Zhang","year":"2022","unstructured":"Zhang, L., Pan, Y., Xu, Y., Zhang, W., Ma, W., Ibrahim, Y. M., Werid, G. M., Zhang, H., Xia, C., Wei, P., et al. (2022). Paraoxonase-1 facilitates PRRSV replication by interacting with viral nonstructural protein-9 and inhibiting type I interferon pathway. Viruses, 14, 1203.","journal-title":"Viruses"},{"key":"62_CR44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579, 270\u2013273.","journal-title":"Nature"}],"container-title":["Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12275-023-00062-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12275-023-00062-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12275-023-00062-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T17:52:26Z","timestamp":1735062746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12275-023-00062-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s12275-023-00062-4","relation":{},"ISSN":["1225-8873","1976-3794"],"issn-type":[{"value":"1225-8873","type":"print"},{"value":"1976-3794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}